Biggest News Aggregation in the World
📰 Nasdaq Prtk News

Page 4 - Nasdaq Prtk News Today

Fast, Ad-Free News Updates

Stay updated with breaking news from Nasdaq Prtk. Real-time updates on events, politics, business and more.

Critical Comparison: Paratek Pharmaceuticals (NASDAQ:PRTK) & IMV (NASDAQ:IMV)

Paratek Pharmaceuticals (NASDAQ:PRTK – Get Rating) and IMV (NASDAQ:IMV – Get Rating) are both small-cap medical companies, but which is the better investment? We will contrast the two businesses based on the strength of their valuation, earnings, dividends, profitability, risk, institutional ownership and analyst recommendations. Analyst Ratings This is a breakdown of current ratings and […]
Tufts University United States Paratek Pharmaceuticals Biomedical Advanced Research Paratek Pharmaceuticals Inc Development Authority

Paratek Pharmaceuticals, Inc. (NASDAQ:PRTK) Expected to Announce Earnings of -$0.35 Per Share

Analysts expect that Paratek Pharmaceuticals, Inc. (NASDAQ:PRTK – Get Rating) will announce ($0.35) earnings per share (EPS) for the current quarter, Zacks Investment Research reports. Two analysts have made estimates for Paratek Pharmaceuticals’ earnings, with the lowest EPS estimate coming in at ($0.35) and the highest estimate coming in at ($0.34). Paratek Pharmaceuticals reported earnings […]
Goldman Sachs Group Inc Paratek Pharmaceuticals Zacks Investment Research Paratek Pharmaceuticals Inc Worth Venture Partners J Goldman Co

Head-To-Head Contrast: Paratek Pharmaceuticals (NASDAQ:PRTK) vs. Kintara Therapeutics (NASDAQ:KTRA)

Paratek Pharmaceuticals (NASDAQ:PRTK – Get Rating) and Kintara Therapeutics (NASDAQ:KTRA – Get Rating) are both small-cap medical companies, but which is the superior stock? We will compare the two companies based on the strength of their earnings, valuation, profitability, risk, analyst recommendations, dividends and institutional ownership. Profitability This table compares Paratek Pharmaceuticals and Kintara Therapeutics’ […]
Tufts University United States San Diego Paratek Pharmaceuticals Get Rating Paratek Pharmaceuticals Biomedical Advanced Research

Paratek Pharmaceuticals, Inc. (NASDAQ:PRTK) Expected to Post Quarterly Sales of $27.15 Million

Equities research analysts expect that Paratek Pharmaceuticals, Inc. (NASDAQ:PRTK – Get Rating) will report sales of $27.15 million for the current fiscal quarter, according to Zacks. Two analysts have provided estimates for Paratek Pharmaceuticals’ earnings. The highest sales estimate is $27.30 million and the lowest is $27.00 million. Paratek Pharmaceuticals posted sales of $16.43 million […]
Paratek Pharmaceuticals Get Rating Paratek Pharmaceuticals Zacks Investment Research Manufacturers Life Insurance Company Paratek Pharmaceuticals Inc Invesco Ltd

Stay Updated with Latest News

Get breaking news updates delivered to your inbox

Browse All News →

$27.15 Million in Sales Expected for Paratek Pharmaceuticals, Inc. (NASDAQ:PRTK) This Quarter

Wall Street brokerages expect Paratek Pharmaceuticals, Inc. (NASDAQ:PRTK – Get Rating) to post sales of $27.15 million for the current fiscal quarter, Zacks reports. Two analysts have issued estimates for Paratek Pharmaceuticals’ earnings, with the lowest sales estimate coming in at $27.00 million and the highest estimate coming in at $27.30 million. Paratek Pharmaceuticals reported […]
Paratek Pharmaceuticals Zacks Investment Research Paratek Pharmaceuticals Inc Cubist Systematic Strategies Paratek Pharmaceuticals Company Profile Get Rating Citigroup Inc

Weekly Research Analysts' Ratings Changes for Paratek Pharmaceuticals (PRTK)

A number of firms have modified their ratings and price targets on shares of Paratek Pharmaceuticals (NASDAQ: PRTK) recently: 3/31/2022 – Paratek Pharmaceuticals is now covered by analysts at StockNews.com. They set a “sell” rating on the stock. 3/18/2022 – Paratek Pharmaceuticals was downgraded by analysts at Zacks Investment Research from a “hold” rating to […]
United States Paratek Pharmaceuticals Zacks Investment Research American Investors Co Blackrock Inc Paratek Pharmaceuticals Inc

Paratek Pharmaceuticals (NASDAQ:PRTK) PT Lowered to $22.00

Paratek Pharmaceuticals (NASDAQ:PRTK – Get Rating) had its price target reduced by equities research analysts at HC Wainwright from $27.00 to $22.00 in a note issued to investors on Thursday, The Fly reports. The firm currently has a “buy” rating on the specialty pharmaceutical company’s stock. Several other research firms have also recently commented on […]
Paratek Pharmaceuticals Get Rating Paratek Pharmaceuticals Zacks Investment Research Manufacturers Life Insurance Company Norges Bank Blackrock Inc

Paratek Pharmaceuticals (NASDAQ:PRTK) Issues Earnings Results, Misses Expectations By $0.25 EPS

Paratek Pharmaceuticals (NASDAQ:PRTK – Get Rating) announced its quarterly earnings results on Monday. The specialty pharmaceutical company reported ($0.66) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.41) by ($0.25), Fidelity Earnings reports. During the same period in the previous year, the firm earned ($0.49) EPS. Paratek Pharmaceuticals updated its FY 2022 […]
Paratek Pharmaceuticals Get Rating Geode Capital Management Paratek Pharmaceuticals Zacks Investment Research Norges Bank Blackrock Inc

We Analyzed the Future Direction of Paratek Pharmaceuticals Inc. (PRTK), Here is What We Found

Paratek Pharmaceuticals Inc. (NASDAQ:PRTK) went up by 5.39% from its latest closing price compared to the recent 1-year high of $11.23. The company’s stock price has collected -1.96% of loss in the last five trading sessions. Press Release reported 10 hours ago that China’s National Medical
Warren Buffett Brenner Randall Development Regulatory Of Paratek Pharmaceuticals Inc It Worth Investing In Paratek Pharmaceuticals Inc Paratek Pharmaceuticals Inc China National Medical Products Administration Approves

Explore More Categories

World News India News Business Technology Sports Entertainment Health Science